GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702
Phase 1
Completed
- Conditions
- Cognitive Disorders
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00950586
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents
Phase 2
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: GSK's investigational vaccine 692342Biological: Placebo
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00950612
- Locations
- 🇿🇦
GSK Investigational Site, Worcester, Western Province, South Africa
Study of Salmeterol (SN408D) for Adult Asthma
Phase 4
Completed
- Conditions
- AsthmaBronchial Asthma
- Interventions
- Drug: Hokunalin (tulobuterol) tapeDrug: Salmeterol(SN408D)
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 367
- Registration Number
- NCT00950794
Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children
Phase 3
Completed
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: Pneumococcal vaccine GSK1024850A
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 466
- Registration Number
- NCT00950833
- Locations
- 🇨🇿
GSK Investigational Site, Znojmo, Czechia
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
Phase 2
Completed
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT00950755
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT00950807
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
Phase 3
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Procedure: Blood samplingProcedure: Cervico-vaginal secretion (CVS) samples
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 525
- Registration Number
- NCT00947115
- Locations
- 🇵🇱
GSK Investigational Site, Poznan, Poland
A Study to Evaluate the Effect of Repeat Doses of GW870086X in Mild to Moderate Asthmatics
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT00945932
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Subcutaneous Administration of Otelixizumab to T1DM Patients
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT00946257
- Locations
- 🇧🇪
GSK Investigational Site, Merksem, Belgium
Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00945503
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
© Copyright 2025. All Rights Reserved by MedPath